Is Your Patient with Uncontrolled Severe Asthma Not Responding to a Biologic?

Maanasi Samant; Mario Castro

doi:10.1016/j.jaip.2019.05.021

Is Your Patient with Uncontrolled Severe Asthma Not Responding to a Biologic?

Division of Pulmonary & Critical Care Medicine

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	2284-2285
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	7
Issue number	7
DOIs	https://doi.org/10.1016/j.jaip.2019.05.021
State	Published - Sep 1 2019

Access to Document

10.1016/j.jaip.2019.05.021

Cite this

@article{09f6cc9abcbe417e93fb2f88cf82efbd,

title = "Is Your Patient with Uncontrolled Severe Asthma Not Responding to a Biologic?",

author = "Maanasi Samant and Mario Castro",

note = "Funding Information: Conflicts of interest: M. Samant declares no relevant conflicts of interest. M. Castro has received speaker/consultancy fees from Genentech, Pulmatrix, VIDA; has received research support and speaker/consultancy fees from Sanofi-aventis, Regeneron, AstraZeneca, Boeringer Ingelheim, Teva, and GlaxoSmithKline; receives royalties from Elsevier; and has received research support from Chiesi, Gossamer, Novartis, the National Institutes of Health, the American Lung Association, and Patient-Centered Outcomes Research Institute. Conflicts of interest: M. Samant declares no relevant conflicts of interest. M. Castro has received speaker/consultancy fees from Genentech, Pulmatrix, VIDA; has received research support and speaker/consultancy fees from Sanofi-aventis, Regeneron, AstraZeneca, Boeringer Ingelheim, Teva, and GlaxoSmithKline; receives royalties from Elsevier; and has received research support from Chiesi, Gossamer, Novartis, the National Institutes of Health, the American Lung Association, and Patient-Centered Outcomes Research Institute. Funding Information: Conflicts of interest: M. Samant declares no relevant conflicts of interest. M. Castro has received speaker/consultancy fees from Genentech, Pulmatrix, VIDA; has received research support and speaker/consultancy fees from Sanofi-aventis, Regeneron, AstraZeneca, Boeringer Ingelheim, Teva, and GlaxoSmithKline; receives royalties from Elsevier; and has received research support from Chiesi, Gossamer, Novartis, the National Institutes of Health, the American Lung Association, and Patient-Centered Outcomes Research Institute.",

year = "2019",

month = sep,

day = "1",

doi = "10.1016/j.jaip.2019.05.021",

language = "English",

volume = "7",

pages = "2284--2285",

journal = "Journal of Allergy and Clinical Immunology: In Practice",